P38 MAPK signaling mediates IL-17-induced nitric oxide synthase expression in bone marrow cells

Growth Factors

Volumn 27, Issue 2, 2009, Pages 79-90

  Krstić, Aleksandra ^a   Ilić, Vesna ^a   Mojsilović, Slavko ^a   Jovčić, Gordana ^a   Milenković, Pavle ^a   Bugarski, Diana ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Bone marrow; CFU E; IL 17; MAPK; NOS

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 17; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; STRESS ACTIVATED PROTEIN KINASE; ENZYME INHIBITOR; NOS2 PROTEIN, MOUSE; NOS3 PROTEIN, MOUSE; RECOMBINANT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE MARROW CELL; COLONY FORMING UNIT E; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; CBA MOUSE; CELL CULTURE; CLONOGENIC ASSAY; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENETICS; METABOLISM; MOUSE;

MURINAE;

ANIMALS; BONE MARROW CELLS; CELLS, CULTURED; COLONY-FORMING UNITS ASSAY; ENZYME INHIBITORS; INTERLEUKIN-17; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED CBA; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; NITRIC OXIDE SYNTHASE TYPE III; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RECOMBINANT PROTEINS; RNA, MESSENGER;

EID: 66949146946     PISSN: 08977194     EISSN: 10292292     Source Type: Journal    
DOI: 10.1080/08977190902757153     Document Type: Article

References (55)

1. Aicher A, Heeschen C, Mildner-Rihm C, Urbich C, Ihling C, Technau-Ihling K, Zeiher AM, Dimmeler S. 2003. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat Med 9:1370-1376.
2. Angulo I, Rodriguez R, Garcia B, Medina M, Navarro J, Subiza JL. 1995. Involvement of nitric oxide in bone marrow-derived natural suppressor activity. Its dependence on IFN-gamma. J Immunol 155:15-26.
3. Baksh D, Song L, Tuan RS. 2004. Adult mesenchymal stem cells: Characterization, differentiation, and application in cell and gene therapy. J Cell Mol Med 8:301-316.
4. Barthlen W, Klemens C, Rogenhofer S, Stadler J, Unbehaun N, Holzmann B. 2000. Critical role of nitric oxide for proliferation and apoptosis of bone-marrow cells under septic conditions. Ann Hematol 79:249-254.
5. Beleslin-Ćokić BB, Ćokić VP, Yu X, Weksler BB, Schechter AN, Noguchi CT. 2004. Erythropoiethin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cells. Blood 104:2073-2080.
6. Bianco P, Riminucci M, Gronthos S, Robey PG. 2001. Bone marrow stromal stem cells: Nature, biology and potential application. Stem Cells 19:180-192.
7. Bugarski D, Krstić A, Vlaśki M, PetakovM, Jovćić G, Stojanović N, Milenković P. 2004. Interleukine-17-induced inhibitory effect on late stage murine erythroid bone marrow progenitors. Eur Cytokine Netw 15:247-254.
8. Bugarski D, Krstić A, Mojsilović S, Vlaśki M, Petakov M, Jovčić G, Stojanović N, Milenković P. 2007. Signaling pathways implicated in haematopoietic progenitor cell proliferation and differentiation. Exp Biol Med 232:156-163.
9. Cirino G, Fiorucci S, Sessa WC. 2003. Endothelial nitric oxide synthase: The Cinderella of inflammation? Trends Pharmacol Sci 24:91-95.
10. Connelly L, Palacios-Callender M, Ameixa C, Moncada S, Hobbs AJ. 2001. Biphasic regulation of NF-kappa B activity underlies the pro- and anti-inflammatory actions of nitric oxide. J Immunol 166:3873-3881.
11. Connelly L, Jacobs AT, Palacios-Callender M, Moncada S, Hobbs AJ. 2003. Macrophage endothelial nitric-oxide synthase autoregulates cellular activation and pro-inflammatory protein expression. J Biol Chem 278:26480-26487.
12. Damoulis PD, Drakos DE, Gagari E, Kaplan DL. 2007. Osteogenic differentiation of human mesenchymal bone marrow cells in silk scaffolds is regulated by nitric oxide. Ann NY Acad Sci 1117: 367-376.
13. Forlow SB, Schurr JR, Kolls JK, Bagby GJ, Schwarzenberger PO, Ley K. 2001. Increased granulopoiesis through interleukin-17 and granulocyte-colony-stimulating factor in leukocyte adhesion molecule-deficient mice. Blood 98:3309-3314.
14. Forstermann U, Boissel JP, Kleinert H. 1998. Expressional control of the 'constitutive' isoforms of nitric oxide synthase (NOS I and NOS III). FASEB J 12:773-790.
15. Fossiez F, Banchereau J, Murray R, Van Kooten C, Garrone P, Lebecque S. 1998. Interleukin-17. Intern Rev Immunol 16: 541-551.
16. Guillot PV, Cui W, Fisk NM, Polak DJ. 2007. Stem cell differentiation and expansion for clinical applications of tissue engineering. J Cell Mol Med 11:935-944.
17. Helfrich MH, Evans DE, Grabowski PS, Pollock JS, Ohshima H, Ralston SH. 1997. Expression of nitric oxide synthase isoforms in bone and bone cell cultures. J Bone Miner Res 12:1108-1115.
18. Huang W, La Russa V, Alzoubi A, Schwarzenberger P. 2006. Interleukin-17A: A T-cell-derived growth factor for murine and human mesenchymal stem cells. Stem Cells 24:1512-1518.
19. Iwakura A, Shastry S, Luedemann C, Hamada H, Kawamoto A, Kishore R, Zhu Y, Qin G, Silver M, Thorne T, Eaton L, Masuda H, Asahara T, Losordo DW. 2006. Estradiol enhances recovery after myocardial infarction by augmenting incorporation of bone marrow-derived endothelial progenitor cells into sites of ischemia-induced neovascularization via endothelial nitric oxide synthase-mediated activation of matrix metalloproteinase-9. Circulation 113:1605-1614.
20. Jacobs-Helber SM, Sawyer ST. 2004. Jun N-terminal kinase promotes proliferation of immature erythroid cells and erythropoietin-dependent cell lines. Blood 104:696-703.
21. Jovčić G, Bugarski D, Petakov M, Stanković J, Stojanović N, Milenković P. 2001. Effect of IL-17 on in vitro haematopoietic progenitor cells growth and cytokine release in normal and post-irradiated murine bone marrow. Growth Factors 19: 61-71.
22. Jovčić G, Bugarski D, PetakovM, Krstić A, Vlaśki M, Stojanović N, Milenković P. 2004. In vivo effects of interleukin-17 on haematopoietic cells and cytokine release in normal mice. Cell Prolif 37:401-412.
23. Kawaguchi M, Adachi M, Oda N, Kokubu F, Huang SK. 2004. IL-17 cytokine family. J Allergy Clin Immunol 114:1265-1273.
24. Kim YM, Bombeck CA, Billiar TR. 1999. Nitric oxide as a bifunctional regulator of apoptosis. Circ Res 84:253-256.
25. Kolonics A, Apati A, Janossy J, Brozik A, Gati R, Schaefer A, Magocsi M. 2001. Activation of the Raf/ERK1/2 MAP kinase pathway is involved in GM-CSF-induced proliferation and survival but not in erythropoietin-induced differentiation of TF-1 cells. Cell Signal 13:743-754.
26. Krasnov P, Michurina T, Packer MA, Stasiv Y, Nakaya N, Moore KA, Drazan KE, Enikolopov G. 2008. Neuronal nitric oxide synthase contributes to the regulation of haematopoiesis. Mol Med 14:141-149.
27. Landmesser U, Engberding N, Bahlmann FH, Schaefer A, Wiencke A, Heineke A, Spiekermann S, Hilfiker-Kleiner D, Templin C, KotlarzD, Mueller M, Fuchs M, Hornig B, Haller H, Drexler H. 2004. Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation 110: 1933-1939.
28. Li H, Wallerath T, Forstermann U. 2002a. Physiological mechanisms regulating the expression of endothelial-type NO synthase. Nitric Oxide 7:132-147.
29. Li H, Wallerath T, Munzel T, Forstermann U. 2002b. Regulation of endothelial-type NO synthase expression in pathophysiology and in response to drugs. Nitric Oxide 7:149-164.
30. Liu Z, Jiang Y, Hao H, Gupta K, Xu J, Chu L, McFalls EO, Zweier JL, Verfaillie CM, Bache RJ. 2007. Endothelial nitric oxide synthase is dynamically expressed during bone marrow stem cell differentiation into endothelidal cells. Am J Physiol Heart Circ Physiol 293:H1760-H1765.
31. Maciejewski JP, Selleri C, Sato T, Cho HJ, Keefer LK, Nathan CF, Young NS. 1995. Nitric oxide suppression of human haematopoiesis in vitro Contribution to inhibitory action of interferon-gamma and tumor necrosis factor-alpha. J Clin Invest 96: 1085-1092.
32. Martel-Pelletier J, Mineau F, Jovanović D, Di Battista JA, Pelletier JP. 1999. Mitogen-activated protein kinase and nuclear factor kappaB together regulate interleukin-17-induced nitric oxide production in human osteoarthritic chondrocytes: Possible role of transactivating factor mitogen-activated protein kinase-activated protein kinase (MAPKAPK). Arthritis Rheum 42: 2399-2409.
33. Michel T, Feron O. 1997. Nitric oxide synthases: Which, where, how and why? J Clin Invest 100:2146-2152.
34. Michurina T, Krasnov P, Balazs A, Nakaya N, Visilieva T, Kuzin B, Khrushchov N,Mulligan RC, Enikolopov G. 2004. Nitric oxide is a regulator of haematopoietic stem cell activity. Mol Ther 10: 241-248.
35. Miljković D, Trajković V. 2004. Inducible nitric oxide synthase activation by interleukin-17. Cytokine Growth Factor Rev 15: 21-32.
36. Miljković D, Cvetković I, Vućković O, Stośić-Grujićić S, Mostarica-Stojković M, Trajković V. 2003. The role of interleukin-17 in inducible nitric oxide synthase-mediated nitric oxide production in endothelial cells. Cell Mol Life Sci 60:518-525.
37. Miljković D, Cvetković I, Momćilović M, Maksimović-Ivanić D, Stośić-Grujićić S, Trajković V. 2005. Interleukin-17 stimulates inducible nitric oxide synthase-dependent toxicity in mouse beta cells. Cell Mol Life Sci 62:2658-2668.
38. Nagata Y, Takahashi N, Davis RJ, Todokoro K. 1998. Activation of p38 MAP kinase and JNK but not ERK is required for erythropoietin-induced erythroid differentiation. Blood 92: 1859-1869.
39. Ozuyaman B, Ebner P, Niesler U, Ziemann J, Kleinbongard P, Jax T, Godecke A, Kelm M, Kalka C. 2005. Nitric oxide differentially regulates proliferation and mobilization of endothelial progenitor cells but not of haematopoietic stem cells. Thromb Haemost 94:770-772.
40. Platanias LC. 2003. Map kinase signaling pathways and hematological malignancies. Blood 101:4667-4679.
41. Punjabi CJ, Laskin DL, Heck DE, Laskin JD. 1992. Production of nitric oxide by murine bone marrow cells. Inverse correlation with cellular proliferation. J Immunol 149:2179-2184.
42. Sasaki K, Heeschen C, Aicher A, Ziebart T, Honold J, Urbich C, Rossig L, Koehl U, Koyanagi M, Mohamed A, Brandes RP, Martin H, Zeiher AM, Dimmeler S. 2006. Ex vivo pretreatment of bone marrow mononuclear cells with endothelial NO synthase enhancer AVE9488 enhances their functional activity for cell therapy. Proc Natl Acad Sci USA 103:14537-14541.
43. Schwarzenberger P, La Russa V, Miller A, Ye P, Huang W, Zieske A, Nelson S, Bagby GJ, Stoltz D, Mynatt RL, Spriggs M, Kolls JK. 1998. IL-17 stimulates granulopoiesis in mice: Use of an alternate, novel gene therapy-derived method for in vivo evaluation of cytokines. J Immunol 161:6383-6389.
44. Schwarzenberger P, Huang W, Oliver P, Byrne P, La Russa V, Zhang Z, Kolls JK. 2001. IL-17 mobilizes peripheral blood stem cells with short- and long-term repopulating ability in mice. J Immunol 167:2081-2086.
45. Shalom-Barak T, Quach J, Lotz M. 1998. Interleukin-17-induced gene expression in articular chondrocytes is associated with activation of mitogen-activated protein kinases and NF-kappaB. J Biol Chem 273:27467-27473.
46. + human bone marrow cells. Blood 87:977-982.
47. Silvestre JS, Tamarat R, Ebrahimian TG, Le-Roux A, Clergue M, Emmanuel F, Duriez M, Schwartz B, Branellec D, Levy BI. 2003. Vascular endothelial growth factor-B promotes in vivo angiogenesis. Circ Res 93:114-123.
48. Stockinger B, Veldhoen M. 2007. Differentiation and function of Th17 T cells. Curr Opin Immunol 19:281-286.
49. Tsukahara H, Hori C, Hiraoka M, Mayumi M, Okada T, Gejyo F. 1997. Nitric oxide modulation of erythropoiesis in rats. Blood 90:473-474.
50. Urao N, Okigaki M, Yamada H, Aadachi Y, Matsuno K, Matsui A, Matsunaga S, Tateishi K, Nomura T, Takahashi T, Tatsumi T, Matsubara H. 2006. Erythropoietin-mobilized endothelial progenitors enhance reendothelialization via Akt-endothelial nitric oxide synthase activation and prevent neointimal hyperplasia. Circ Res 98:1405-1413.
51. Van Bezooijen RL, Papapoulos SE, Lowik CW. 2001. Effect of interleukin-17 on nitric oxide production and osteoclastic bone resorption: Is there dependency on nuclear factor-kappaB and receptor activator of nuclear factor kappaB (RANK)/RANK ligand signaling? Bone 28:378-386.
52. Verma A, Deb DK, Sassano A, Kambhampati S, Wickrema A, Uddin S, Mohindru M, Van Besien K, Platanias LC. 2002a. Cutting edge: Activation of the p38 mitogen-activated protein kinase signaling pathway mediates cytokine-induced hemopoietic suppression in aplastic anemia. J Immunol 168:5984-5988.
53. Verma A, Deb DK, Sassano A, Uddin S, Varga J, Wickrema A, Platanias LC. 2002b. Activation of the p38 mitogen-activated protein kinase mediates the suppressive effects of type I interferons and transforming growth factor-β on normal haematopoiesis. J Biol Chem 277:7726-7735.
54. Villalobo A. 2006. Nitric oxide and cell proliferation. FEBS J 273: 2329-2344.
55. Wuyts WA, Vanaudenaerde BM, Dupont LJ, Van Raemdonck DE, Demedts MG, Verleden GM. 2005. Interleukin-17-induced interleukin-8 release in human airway smooth muscle cells: Role for mitogen-activated kinases and nuclear factor-κB. J Heart Lung Transplant 24:875-881.